Interferon therapy in multiple sclerosis. Mechanism of action, side effects, results
Huber, M.
Der Nervenarzt 59(9): 514-520
1988
ISSN/ISBN: 0028-2804 PMID: 2460777 Document Number: 315599
Document emailed within 1 workday
Related Documents
Pérez Castrillón, J.L.; Cano-del Pozo, M.; Sanz-Izquierdo, S.; Velayos-Jiménez, J.; Dib-Wobakin, W. 2003: Bone mineral density in patients with multiple sclerosis: the effects of interferon Revista de Neurologia 36(10): 901-903Hagenfeldt, K. 1980: Prostaglandins: mechanism of action and side effects of intrauterine devices Contraception Fertilite Sexualite 8(9): 669-673
Shearman, R.P. 1965: The Mechanism of Action of Oral Contraceptives and their Side effects in Clinical Practice Medical Journal of Australia 1(3): 68-70
Demina, T.L.; Khachanova, N.V.; Davydovskaia, M.V. 2005: Use of beta-interferon in the treatment of multiple sclerosis: high-rate injectable dose therapy Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova 105(5): 76-79
Kastrukoff, L.F.; Oger, J.J.; Tourtellotte, W.W.; Sacks, S.L.; Berkowitz, J.; Paty, D.W. 1991: Systemic lymphoblastoid interferon therapy in chronic progressive multiple sclerosis. II. Immunologic evaluation Neurology 41(12): 1936-1941
Stahl, S.M. 1998: Selecting an antidepressant by using mechanism of action to enhance efficacy and avoid side effects Journal of Clinical Psychiatry 59(Suppl): 23-29
Du Toit, D.F.; Heydenrych, J.J. 1986: The application, mechanism of action and side-effects of immunosuppressive agents in clinical transplantation South African Medical Journal 70(11): 687-691
Arase, Y. 2006: Side effects of interferon therapy for chronic hepatitis C Nihon Rinsho. Japanese Journal of Clinical Medicine 64(7): 1363-1367
Chang, L.W.; Liranzo, M.; Bergfeld, W.F. 1995: Cutaneous side effects associated with interferon-alpha therapy: a review Cutis 56(3): 144
Guest, S. 2009: Tamoxifen therapy for encapsulating peritoneal sclerosis: mechanism of action and update on clinical experiences Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis 29(3): 252-255
Rostaing, L.; Izopet, J.; Baron, E.; Duffaut, M.; Puel, J.; Durand, D. 1995: Treatment of chronic hepatitis C with recombinant alpha 2b interferon in kidney transplant recipients: preliminary results and side effects Transplantation Proceedings 27(1): 948-950
Danilova, L.V.; Popova, E.V.; Kulakova, O.G.; Tsareva, E.I.; Favorov, A.V.; Favorova, O.O.; Boĭko, A.N. 2014: The activation of the type i interferon signaling pathway in multiple sclerosis patients treated with russian analogue of Β-interferon-1b: transcriptome profiling data Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova 114(2 Part 2): 72-77
Reclos, G.J.; Baxevanis, C.N.; Sfagos, C.; Papageorgiou, C.; Tsokos, G.C.; Papamichail, M. 1987: Multiple sclerosis: II. Effects of prothymosin alpha on the autologous and allogeneic MLR in patients with multiple sclerosis Clinical and Experimental Immunology 70(2): 336-344
Kuntz, E. 1982: Constipation and constipation treatment. 2. Laxatives--mechanism of action, indications and side effects Fortschritte der Medizin 100(26): 1235-1239
Rieckmann, P. 2001: Early multiple sclerosis therapy in the effects of public health economics Medizinische Klinik 96(Suppl 1): 17-21
Burnfield, S. 1978: Multiple sclerosis: the emotional side Nursing Times 74(19): Suppl: 132-133
Alciato, P.; Cantone, P.A.; Fico, D.; Gagliardini, R.; Petrella, V. 1990: Bamifylline in the therapy of asthmatic syndromes. Efficacy and side effects vs delayed-action theophylline anhydride Minerva Medica 81(1-2): 93-97
Wilson, B.A. 1995: Interferon beta for treatment of multiple sclerosis Medsurg Nursing: Official Journal of the Academy of Medical-Surgical Nurses 4(2): 151-153
Lebrun, C. 2001: Beta-interferon clinical trials using MRI in patients with multiple sclerosis Revue Neurologique (Paris) 157(8-9 Part 1): 761-767
Cardy, P. 1997: Interferon beta in multiple sclerosis. Relapses deserve treatment Bmj 314(7080): 602